Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038934 | 1.00 | TK1 (0.41) | TK1HPGDTYMPNT5MBCHE | |
| SCHEMBL28618584 | 0.90 | TK1 (0.39) | TK1HPGDTYMPNT5MBCHE | |
| SCHEMBL5696121 | 0.90 | TK1 (0.39) | TK1HPGDTYMPNT5MBCHE | |
| SCHEMBL28618582 | 0.90 | TK1 (0.39) | TK1HPGDTYMPNT5MBCHE | |
| SCHEMBL5696099 | 0.89 | TK1 (0.43) | TK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL11981128 | 0.88 | TK1 (0.42) | TK1HPGDTYMPNT5MALDH1A1 | |
| SCHEMBL20394057 | 0.87 | TK1 (0.37) | TK1HPGDTYMPNT5MBCHE | |
| SCHEMBL28749276 | 0.87 | TK1 (0.37) | TK1HPGDTYMPNT5MBCHE | |
| SCHEMBL20394055 | 0.87 | TK1 (0.37) | TK1HPGDTYMPNT5MBCHE | |
| SCHEMBL20394035 | 0.85 | TK1 (0.41) | TK1HPGDTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501848-B1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA AS (DK) | 2007-08-08 | — | — | EP | claimed |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2004-01-22 | — | — | US | claimed |
| US-8492390-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2013-07-23 | — | — | US | disclosed |
| US-20120165514-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-8084458-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2011-12-27 | — | — | US | disclosed |
| US-20100216983-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S, a Denmark corporation | 2010-08-26 | — | — | US | disclosed |
| US-7569575-B2 | Formed via intermediates which are reactive with nucleophiles | SANTARIS PHARMA A/S (DK) | 2009-08-04 | — | — | US | disclosed |
| EP-1501848-B1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA AS (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1163250-B1 | IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES | EXIQON AS (DK) | 2006-07-12 | — | — | EP | disclosed |
| US-6734291-B2 | SULFONYLATION OF A DI(HYDROXYMETHANE)FURO(2,3-D)1,3-DIOXOLE DERIVATIVE WITH A SULFONYL HALIDE | EXIQON A/S (DK) | 2004-05-11 | — | — | US | disclosed |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2004-01-22 | — | — | US | disclosed |
| US-6639059-B1 | Novel synthesis strategy comprising novel key intermediate, (2.2.1)bicyclo nucleosides are produced at least two steps shorter than any previously known strategy; 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-alpha-D-ribofuranose | EXIQON A/S (DK) | 2003-10-28 | — | — | US | disclosed |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | EXIQON A/S | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216983-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | RNGTT, NSUN3, NSUN2 | TK1 195/4885HPGD 2243/4885TYMP 67/4885 |
| US-20120165514-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | RNGTT, NSUN3, NSUN2 | TK1 195/4885HPGD 2243/4885TYMP 67/4885 |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | NSUN3, RNGTT, NSUN2 | TK1 86/4885HPGD 2626/4885TYMP 61/4885 |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | NSUN2, RNGTT, RNMT | TK1 72/4885HPGD 3399/4885TYMP 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.